Company intelligence / Profile preview

SinoMab BioScience Limited

Pak Shek Kok, New Territories, Hong Kongsinomab.com ↗

Ownership: Private
Employees: ~214
Development stage: Phase 3

Overview

The company's flagship product SM03 (Suciraslimab) has completed Phase III clinical trials for rheumatoid arthritis in China, met its primary endpoint in April 2023, and is pending NMPA's marketing approval. The biologics license application (BLA) was accepted on September 5, 2023, and necessary inspections were completed in January 2024.

Therapeutic areas: NeurologyImmunologyDermatologyPulmonology
Modalities: Monoclonal antibodies (mAbs)New Chemical Entities (NCEs)Bispecific antibodies
Industry: Biotech

Drug pipeline

6 assets

suciraslimab

5 more assets in the full pipeline.

Beyond the preview

Go deeper on SinoMab BioScience Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SinoMab BioScience Limited.